DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$182.81M, compared with -$147.71M a year earlier.
Context
- Retained earnings amounted to 344.4% of total assets at the end of Q1 FY2026, down 36.0 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -23.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (172.77M) USD
- Year-over-year change
- -23.4%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (172.77M) | -23.4% |
| FY2024 | 2024-12-31 | (140M) | -21.2% |
| FY2023 | 2023-12-31 | (115.56M) | -20.2% |
| FY2022 | 2022-12-31 | (96.18M) | -16.6% |
| FY2021 | 2021-12-31 | (82.5M) | — |
Retained Earnings vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 retained earnings of -$182.81M is the 2nd highest of the 7 companies compared; the peer median is -$901.81M.
- Its year-over-year change of -23.8% is the 3rd highest of 7, against a peer median of -29.9%.
- Retained earnings amounts to 344.4% of total assets for DMAC, versus a peer median of 208.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$140.65M | -39.7% | — | 218.4% | |
| Mar 2026 | -$182.81M | -23.8% | — | 344.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | -$355.67M | -33.8% | — | 89.4% |
| Mar 2026 | -$513.76M | -31.3% | — | 122.4% | |
| Mar 2026 | -$1.29B | -5.9% | — | 440.6% | |
| Mar 2026 | -$1.69B | -1.2% | — | 466.9% | |
| Jun 2026 | -$2.31B | -28.5% | — | 199.3% | |
| Peer median (excluding DMAC) | -$901.81M | -29.9% | — | 208.8% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.